The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

By Hillman A.L.   Schwartz J.S.   Willian M.K.   Peskin E.   Roehrborn C.G.   Oesterling J.E.   Mason M.F.   Maurath C.J.   Deverka P.A.   Padley R.J.  

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 169-178

Elsevier

Access to resources Recommend Favorite

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

By Keetch D.W.   Andriole G.L.   Ratliff T.L.   Catalona W.J.  

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

Laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia

By Chahal R.   Sundaram S.K.  

Urology, Vol. 56, Iss. 3, 2000-09 ,pp. : 546-547

Elsevier

Access to resources Recommend Favorite

Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia

By Shingleton W.B.   Farabaugh P.   May W.  

Urology, Vol. 60, Iss. 2, 2002-08 ,pp. : 305-308

Elsevier

Access to resources Recommend Favorite

A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia

By Cowles R.S.   Kabalin J.N.   Childs S.   Lepor H.   Dixon C.   Stein B.   Zabbo A.  

Urology, Vol. 46, Iss. 2, 1995-08 ,pp. : 155-160

Elsevier

Access to resources Recommend Favorite